<DOC>
	<DOCNO>NCT02645461</DOCNO>
	<brief_summary>Amyotrophic lateral sclerosis ( ALS ) fatal disease lead motor neuron degeneration progressive paralysis . Other study reveal defect skeletal muscle even absence motor neuron anomaly , focus acetylcholine receptor ( AChRs ) support so-called `` dying-back '' hypothesis . Outcome study understand endocannabinoid palmitoylethanolamide ( PEA ) reduce rundown AChRs current ALS muscle , modify ALS patient ' clinical electrophysiological parameter .</brief_summary>
	<brief_title>Acetylcholine Receptors From Human Muscles Pharmacological Target ALS</brief_title>
	<detailed_description>Outcome : Monitoring efficacy safety PEA treatment patient ALS . Analysis AChR current description composition AChRs subunits ALS muscle Design Study : A randomize control blind study . Patients sporadic ALS receive riluzole alone riluzole+PEA order investigate clinical electrophysiological effect treatment . The expected number enrol patient 50 . All patient satisfy selection criterion randomize two group : first group treat riluzole , second group riluzole associate PEA ( Normast 600 mg microgranular , 2 sachets/day ) . The randomization do stratify patietns accord type clinical onset ( bulbar vs. spinal ) . The patient enrol Department Neurology Psychiatry , University Rome `` Sapienza '' . The visit perform 0 ( randomization ) , 3 6 month . At visit ALS Functional Rating Scale-Revised ( ALSFRS-R ) , percentage predict forced vital capacity ( FVC % ) , Medical Research Council ( MRC ) score muscle strength limit right upper limb , compound muscle action potential ( CMAP ) right ulnar phrenic nerve assess . A muscle biopsy do end study . The obtained result compare observed muscle sample denervated ( non-ALS ) control patient .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<mesh_term>Palmidrol</mesh_term>
	<mesh_term>Acetylcholine</mesh_term>
	<criteria>Diagnosis ALS accord ElEscorial criterion ; Age &gt; 18 year ; ALS Functional Rating ScaleRevised ( ALSFRS r ) score &gt; 20 ; Forced Vital Capacity ( FVC ) &gt; 30 % ; Treatment Riluzole . Other disease motor neuron ; Experimental treatment previous three month ; Pregnant breastfeeding ; Contraindications use riluzole ; Patients undergo tracheostomy , enteral parenteral supply ; Severe psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>